{"id":"rivaroxaban-and-ticagrel-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban is a Factor Xa inhibitor that blocks the coagulation cascade, while ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation. Combined, they provide complementary antithrombotic effects through different pathways—one targeting the coagulation cascade and the other targeting platelet function—to reduce clot formation in high-risk cardiovascular conditions.","oneSentence":"Rivaroxaban and ticagrelor together provide dual anticoagulation and antiplatelet therapy to prevent thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:29.278Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with high thrombotic risk"},{"name":"Prevention of thrombotic events in patients requiring dual antithrombotic therapy"}]},"trialDetails":[{"nctId":"NCT02334254","phase":"PHASE4","title":"Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-08","conditions":"Atrial Fibrillation","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3200,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rivaroxaban and ticagrel therapy","genericName":"rivaroxaban and ticagrel therapy","companyName":"Beijing Anzhen Hospital","companyId":"beijing-anzhen-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban and ticagrelor together provide dual anticoagulation and antiplatelet therapy to prevent thrombotic events. Used for Acute coronary syndrome with high thrombotic risk, Prevention of thrombotic events in patients requiring dual antithrombotic therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}